The interaction of psychotropic preparations with immunocompetent targets as the basis for their future nontraditional use

Published data on interactions of some psychotropic drugs with immunocompetent target cells has been reviewed. The observed immunosuppressive, immunostimulating, and immunomodulating activities of the drugs are considered nontraditional. The necessity of more detailed study of mechanisms of such interactions is outlined. Possible use of psychotropic drugs as immunomodulators is proposed.     

Review of the book by A.A. Kudryavtsev,A.S. Smirnov,and L.D. Tsendin “Physics of Glow Discharge”

A new voluminous book on gas-discharge physics is reviewed. It is emphasized that the authors consistently follow a nontraditional approach based on the electron distribution function with allowance for its nonlocal character. This opens new, sometimes unexpected, issues of the well-known phenomena, which is illustrated by the reviewer by using the positive column of a low-pressure glow discharge as an example.     

New Insights into the Roles of Nogo-A in CNS Biology and Diseases

Neurochemical Research - Nogos have become a hot topic for its well-known number Nogo-A’s big role in clinical matters. It has been recognized that the expression of Nogo-A and the receptor...     

Alteration of blood-brain barrier function by methamphetamine and cocaine

The integrity of the blood-brain barrier (BBB) plays an important role in maintaining a safe neural microenvironment in the brain. Loss of BBB integrity has been recognized as a major cause of profound brain alterations. Psychoactive drugs such as methamphetamine (METH) or cocaine are well-known drugs of abuse that can alter the permeability of the BBB via various mechanisms. In addition, the neurotoxicity of METH is well documented, and alterations in BBB function can contribute to this toxicity. A great deal of effort has been devoted to understanding the cellular and molecular mechanisms of the action of these drugs in the central nervous system. However, only a few investigations have focused on the effects of METH and cocaine on BBB function. The aim of this short review is to summarize our present knowledge of this subject.     

Fungal calcineurin complex as an antifungal target: From past to present to future

The serine/threonine phosphatase calcineurin complex has been considered a prospective target for developing novel drugs due to its importance in fungal growth, virulence, and stress responses in pathogenic fungi. Therefore, two well-known immunosuppressants, FK506 and cyclosporine A were successfully identified to inhibit calcineurin by combining with FK506-binding protein 12 and cyclophilin A, respectively. However, these drugs are immunosuppressive and may exhibit serious side effects. There is a growing number of literatures reported on further exploring functions of the calcineurin complex as promising antifungal targets. In general, the majority of the calcineurin complex structures are conserved but some functions are species-specific. Nevertheless, there still have a lot of functional motifs in the calcineurin complex that are unexplored. Therefore, further investigation and experimentation into the calcineurin complex are strongly required. This review not only has summarized previous findings but also explored bioinformatics analysis along with structural models of the calcineurin complex for finding fungal-specific regions as potential targets, laying the groundwork for future research into new therapeutics.     

An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1

Several drugs inhibiting protein kinases have been launched successfully, demonstrating the attractiveness of protein kinases as therapeutic targets. Functional genomics research within both academia and industry has led to the identification of many more kinases as potential drug targets. Although a number of well-known formats are used for measuring protein kinase activity, some less well-characterized protein kinases identified through functional genomics present particular challenges for existing assay formats when there is limited knowledge of the endogenous substrates or activation mechanisms for these novel kinase targets. This is especially the case when a very sensitive assay is required to differentiate often highly potent inhibitors developed by late-stage medicinal chemistry programs. ACK1 is a non-receptor tyrosine kinase that has been shown to be involved in tumorigenesis and metastasis. Here we describe the development of an extremely sensitive high-throughput assay for ACK1 capable of detecting 240 fmol per well of the kinase reaction product employing a BV-tag-based electrochemiluminescence assay. This assay is universally applicable to protein tyrosine kinases using a BV-tag-labeled monoclonal antibody against phosphotyrosine. Furthermore, this assay can be extended to the evaluation of Ser/Thr kinases in those cases where an antibody recognizing the phospho-product is available.     

Targeting protein-protein interactions: lessons from p53/MDM2

The tremendous challenge of inhibiting therapeutically important protein-protein interactions has created the opportunity to extend traditional medicinal chemistry to a new class of targets and to explore nontraditional strategies. Here we review a widely studied system, the interaction between tumor suppressor p53 and its natural antagonist MDM2, for which both traditional and nontraditional approaches have been reported. This system has been a testing ground for novel proteomimetic scaffold-based strategies, i.e., for attempts to mimic the recognition surface displayed by a folded protein with unnatural oligomers. Retroinverso peptides, peptoids, terphenyls, beta-hairpins, p-oligobenzamides, beta-peptides, and miniproteins have all been explored as inhibitors of the p53/MDM2 interaction, and we focus on these oligomer-based efforts. Traditional approaches have been successful as well, and we briefly review small molecule inhibitors along with other strategies for reactivation of the p53 pathway, for comparison with oligomer- based approaches. We close with comments on an emerging dichotomy among protein-protein interaction targets.     

Pharmacologic control of the hormonally modulated immune response. III. Prolongation of allogeneic skin graft rejection and prevention of runt disease by a combination of drugs acting on neuroendocrine functions.

A recently developed pharmacologic means for suppressing acquired immunity by drugs acting on neuroendocrine regulation has been applied to transplantation immune reactions. A number of drugs have been tested singly and in combination for their capacity to suppress the immune response of mice grafted with allogeneic skin. Another model involved newborn F1 hybrid recipients inoculated with spleen cells from donors of parental strains that had been made specifically "unresponsive" by drug and alloantigen treatment. These procedures led to the identification of a combination of four drugs that induced a remarkable delay in allograft rejection and a prolonged unresponsiveness to alloantigens. This combination of drugs also abrogated the graft-vs-host-runting syndrome in newborn hybrid recipients.     

Study by HPLC-MS of the interaction of platinum antitumor complexes with potato carboxypeptidase inhibitor (PCI)

The interaction of the well-known antitumor drug cisplatin cis-[PtCl(2)(NH(3))(2)] and the compound trans-[PtCl(2)NH(3)(4-hydroxymethylpyridine)] with the small protein potato carboxypeptidase inhibitor (PCI) and a PCI mutant in which glycine-39 was substituted by methionine has been followed by HPLC/mass spectrometry. Our results showed that both Pt drugs were able to bind PCI through Met-39 and histidines in mutated PCI, whereas only the trans complex interacted significantly with wild PCI. In the cytotoxic studies, the monofunctional adduct PCI-Met-cisplatin was neither more active nor more selective than cisplatin itself when tested against three tumor cell lines with different number of EGF receptors. Those results suggested that the poor activity of the adduct could be just due to the small fraction of cisplatin which was decoordinated from the adduct and able to penetrate the tumor cells, as well as to the changes in the structure of the platinum drug after the loss of NH(3) groups upon binding PCI-Met.     

JVG9, a benzimidazole derivative,alters the surface and cytoskeleton of Trypanosoma cruzi bloodstream trypomastigotes

Trypanosoma cruzi has a particular cytoskeleton that consists of a subpellicular network of microtubules and actin microfilaments. Therefore, it is an excellent target for the development of new anti-parasitic drugs. Benzimidazole 2-carbamates, a class of well-known broad-spectrum anthelmintics, have been shown to inhibit the in vitro growth of many protozoa. Therefore, to find efficient anti-trypanosomal (trypanocidal) drugs, our group has designed and synthesised several benzimidazole derivatives. One, named JVG9 (5-chloro-1H-benzimidazole-2-thiol), has been found to be effective against T. cruzi bloodstream trypomastigotes under both in vitro and in vivo conditions. Here, we present the in vitro effects observed by laser scanning confocal and scanning electron microscopy on T. cruzi trypomastigotes. Changes in the surface and the distribution of the cytoskeletal proteins are consistent with the hypothesis that the trypanocidal activity of JVG9 involves the cytoskeleton as a target.     

In vitro efficacy of some cattle drugs on bovine serum paraoxonase 1 (PON1) activity

Serum paraoxonase 1 (EC 3.1.8.1, PON1), a calcium-associated enzyme, has an ability to hydrolyze organophosphate compounds. Related to this property, PON1 has a critical role in antioxidant mechanisms. It is well-known that the enzyme protects LDL from oxidation. In this study we investigated the in vitro inhibitory effects of some drugs. These drugs are oxytocin, dexamethasone, atropine sulphate, gentamicin sulphate, sulfadoxine-trimethoprim, furosemid, metamizole sodium and toldimfos sodium. The IC(50) values obtained varied markedly from 0.014 to 507.72 mg/mL. According to our findings, most potent and significant inhibition was displayed by dexamethasone, atropine sulphate and furosemid.     

GABA and the behavioral effects of anxiolytic drugs

Much recent research has shown that benzodiazepine binding sites in the central nervous system are associated with GABA receptors. It is therefore possible that the pharmacological and therapeutic effects of benzodiazepines and drugs with similar profiles are mediated through GABAergic mechanisms. In this paper the evidence is considered for a possible involvement of GABA in the behavioral effects of anxiolytic drugs. There are a number of reports that the behavioral actions of anxiolytics can be antagonised by GABA antagonists such as bicuculline or picrotoxin but there are many contradictory findings and these drugs are difficult to use effectively in behavioral studies. In general, GABA agonists do not exert anxiolytic-like behavioral effects after systemic injection but intracerebral administration of muscimol has been shown to produce benzodiazepine-like actions. Although a number of questions remain unanswered, current evidence does not provide strong support for a role for GABA in the behavioral effects of anxiolytic drugs.     

Molecular interactions of ruthenium complexes in isolated mammalian nuclei and cytotoxicity on V79 cells in culture

In this paper, the molecular interactions in isolated mammalian nuclei of three ruthenium complexes, which are putative antineoplastic chemotherapeutic agents effective in reducing metastatic tumours in vivo, have been investigated and compared with the well-known antitumour drug CDDP (cis-diamminedichloroplatinum). The compounds studied are: Natrans-RuCl4(DMSO)Imidazole (NAMI), Natrans-RuCl4(DMSO)Oxazole (NAOX) and Natrans-RuCl4(TMSO)- Isoquinoline (TEQU). This study shows that the drugs bind to DNA but induce few, if any, DNA interstrand crosslinks, which are considered as the main biological lesions involved in the cytotoxic activity of several already known antitumour drugs, whilst in the same experimental conditions, CDDP is confirmed to induce them. On the other hand, proteins appear to be an important target in the cell for these drugs, since proteins-DNA crosslinks are shown to be induced by the complexes. Moreover, we investigated Ru complexes for their direct cytotoxicity on V79 cells in culture, showing that two of them (NAMI and NAOX) do not significantly reduce the cloning efficiency of the cells even at concentrations as high as 2-3 mg/ml: only TEQU both reduces cloning efficiency and induces a significant number of mutants in V79 cells in culture.     

The influence of drugs upon the anticoagulant activity of heparin

Although physical incompatibility between heparin and a number of drugs has been reported we did not discover any evidence of such incompatibility when heparin was mixed with 11 commonly used drugs in therapeutic concentrations.Furthermore, there was no detectable change in the anticoagulant activity in the presence of any of these drugs, nor was there any change in the biological activity of the antibiotics tested.     

In vitro efficacy of some cattle drugs on bovine serum paraoxonase 1 (PON1) activity

Serum paraoxonase 1 (EC 3.1.8.1, PON1), a calcium-associated enzyme, has an ability to hydrolyze organophosphate compounds. Related to this property, PON1 has a critical role in antioxidant mechanisms. It is well-known that the enzyme protects LDL from oxidation. In this study we investigated the in vitro inhibitory effects of some drugs. These drugs are oxytocin, dexamethasone, atropine sulphate, gentamicin sulphate, sulfadoxine-trimethoprim, furosemid, metamizole sodium and toldimfos sodium. The IC₅₀ values obtained varied markedly from 0.014 to 507.72?mg/mL. According to our findings, most potent and significant inhibition was displayed by dexamethasone, atropine sulphate and furosemid.     

Recent progress on the development of antibiotics from the genus <Emphasis Type="Italic">Micromonospora</Emphasis>

The emergence of a large number of antimicrobialresistant organisms is a cause for concern. Nature is historically the source of drugs; indeed a considerable number of drugs have been developed from microorganisms, and are now used daily in the treatment of infectious diseases. However, the introduction to the pharmaceutical market of new therapeutic molecules has decreased during the last two decades. In this review, the genus Micromonospora is proposed as a biofactory for production of new antibiotics. The genus Micromonospora has been investigated extensively and more than 100 antibiotics have been isolated from diverse Micromonospora strains. In addition, recent developments in analytical, biological and bioinformatics screening tools used in the discovery of new therapeutic compounds are described. It may be possible to revive formerly used antibiotics produced by Micromonospora and study of this genus may facilitate discovery of novel bioactive molecules.     

Behavioral neuroendocrinology in nontraditional species of mammals: things the 'knockout' mouse CAN'T tell us

The exploration of many of the fundamental features of mammalian behavioral neuroendocrinology has benefited greatly throughout the short history of the discipline from the study of highly inbred, genetically characterized rodents and several other "traditional" exemplars. More recently, the impact of genomic variation in the determination of complex neuroendocrine and behavioral systems has advanced through the use of single and multiple gene knockouts or knockins. In our essay, we argue that the study of nontraditional mammals is an essential approach that complements these methodologies by taking advantage of allelic variation produced by natural selection. Current and future research will continue to exploit these systems to great advantage and will bring new techniques developed in more traditional laboratory animals to bear on problems that can only be addressed with nontraditional species. We highlight our points by discussing advances in our understanding of neuroendocrine and behavioral systems in phenomena of widely differing time scales. These examples include neuroendocrine variation in the regulation of reproduction across seasons in Peromyscus, variation in parental care by biparental male rodents and primates within a single infant rearing attempt, and circadian variation in the regulation of the substrates underlying mating in diurnal vs. nocturnal rodents. Our essay reveals both important divergences in neuroendocrine systems in our nontraditional model species, and important commonalities in these systems.     

Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds

Monoamine oxidase (EC1.4.3.4; MAO) is a mitochondrial outer membrane flavoenzyme that catalyzes the oxidation of biogenic amines. It has two distinct isozymic forms designated MAO-A and MAO-B, each displaying different substrate and inhibitor specificities. They are the well-known targets for antidepressant and neuroprotective drugs. Elucidation of the X-ray crystallographic structure of MAO-B has opened the way for molecular modeling studies. A series of experimentally tested (1-10) model compounds has been docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program was employed to perform automated molecular docking. The free energies of binding (DeltaG) and inhibition constants (K(i)) of the docked compounds were calculated by the Lamarckian Genetic Algorithm (LGA) of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental K(i) values were obtained.